D
Denali Therapeutics Inc. DNLI
$15.49 $0.261.71% NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

06/30/2025 03/31/2025 12/31/2024 09/30/2024 06/30/2024
Revenue -- -- -- -100.00% -99.63%
Total Other Revenue -- -- -- -- --
Total Revenue -- -- -- -100.00% -99.63%
Cost of Revenue -3.30% -3.99% -34.54% -24.92% -27.09%
Gross Profit 2.78% -489.47% -1,109.32% -1,735.23% -1,323.07%
SG&A Expenses 16.02% 7.99% 2.02% -1.91% 0.49%
Depreciation & Amortization -- -- -- -- --
Other Operating Expenses -- -- -- -- --
Total Operating Expenses 5.79% 0.74% -6.21% 0.43% -0.37%
Operating Income -6.06% -138.48% -145.30% -202.41% -208.35%
Income Before Tax -14.14% -230.78% -191.13% -243.52% -226.86%
Income Tax Expenses 126.67% 126.67% 126.67% 600.00% 600.00%
Earnings from Continuing Operations -14.15% -230.75% -191.12% -243.56% -226.90%
Earnings from Discontinued Operations -- -- -- -- --
Extraordinary Item & Accounting Change -- -- -- -- --
Minority Interest in Earnings -- -- -- -- --
Net Income -14.15% -230.75% -191.12% -243.56% -226.90%
EBIT -6.06% -138.48% -145.30% -202.41% -208.35%
EBITDA -5.91% -145.37% -163.60% -234.12% -242.06%
EPS Basic 1.62% -187.36% -144.79% -197.15% -173.05%
Normalized Basic EPS 9.49% -119.64% -121.42% -204.45% -181.30%
EPS Diluted 1.62% -176.04% -136.24% -185.46% -163.45%
Normalized Diluted EPS 9.49% -113.32% -115.11% -193.75% -172.40%
Average Basic Shares Outstanding 14.83% 20.85% 19.71% 15.04% 12.12%
Average Diluted Shares Outstanding 14.83% 20.02% 18.87% 14.23% 11.30%
Dividend Per Share -- -- -- -- --
Payout Ratio -- -- -- -- --